A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

Amit M. Oza[1], Ursula A. Matulonis[2], Angeles Alvarez Secord[3], John Nemunaitis[4], Lynda D. Roman[5], Sarah P. Blagden[6], Susana Banerjee[7], William P. McGuire[8], Sharad Ghamande[9], Michael J. Birrer[10], Gini F. Fleming[11], Merry Jennifer Markham[12], Hal W. Hirte[13], Diane M. Provencher[14], Bristi Basu[15], Rebecca Kristeleit[16], Deborah K. Armstrong[17], Benjamin Schwartz[18], Patricia Braly[19], Geoff D. Hall[20], Kenneth P. Nephew[21], Simone Jueliger[22], Aram Oganesian[23], Sue Naim[23], Yong Hao[23], Harold Keer[23], Mohammad Azab[23], and Daniela Matei[24]

ABSTRACT

Purpose: Platinum resistance in ovarian cancer is associated with epigenetic modifications. Hypomethylating agents (HMA) have been studied as carboplatin resensitizing agents in ovarian cancer. This randomized phase II trial compared guadecitabine, a second-generation HMA, and carboplatin (G+C) against second-line chemotherapy in women with measurable or detectable platinum-resistant ovarian cancer.

Patients and Methods: Patients received either G+C (guadecitabine 30 mg/m^2 s.c. once-daily for 5 days and carboplatin) or treatment of choice (TC; topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine) in 28-day cycles until progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS); secondary endpoints were RECIST v1.1 and CA-125 response rate, 6-month PFS, and overall survival (OS).

Results: Of 100 patients treated, 51 received G+C and 49 received TC, of which 27 crossed over to G+C. The study did not meet its primary endpoint as the median PFS was not statistically different between arms (16.3 weeks vs. 9.1 weeks in the G+C and TC groups, respectively; $P = 0.07$). However, the 6-month PFS rate was significantly higher in the G+C group (37% vs. 11% in TC group; $P = 0.003$). The incidence of grade 3 or higher toxicity was similar in G+C and TC groups (51% and 49%, respectively), with neutropenia and leukopenia being more frequent in the G+C group.

Conclusions: Although this trial did not show superiority for PFS of G+C versus TC, the 6-month PFS increased in G+C treated patients. Further refinement of this strategy should focus on identification of predictive markers for patient selection.

Introduction

Advanced stage high-grade serous ovarian cancer (HGSOC), which is distinctively associated with a p53-mutated signature, has a poor estimated 5-year survival of 50% (1). Although patients with HGSOC usually respond to initial platinum-based chemotherapy, relapses occur in most, leading to the development of platinum-resistance and subsequent death (2, 3). Progression of HGSOC to a platinum-resistant state is caused by multiple mechanisms, including aberrant DNA repair responses, alterations in efflux pump proteins, and accumulated genomic and epigenomic modifications which impact the response of cancer cells to DNA damage. Adaptive responses include increased DNA methylation and modifications of histone marks (4, 5), which cause transcriptional silencing of tumor suppressor genes (TSG) and other genes required for chemotherapy-induced cell death (6, 7).

Given preclinical data demonstrating that targeting DNA methylation to resensitize HGSOC to platinum is possible (8–11), we hypothesized this approach would restore platinum sensitivity in patients with HGSOC (12, 13). With early clinical studies demonstrating feasibility of this strategy (13–16), we set out to determine whether targeting DNA methylation induces clinically meaningful

[1]Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto Canada. [2]Dana-Farber Cancer Institute, Boston, Massachusetts. [3]Duke Cancer Institute, Durham, North Carolina. [4]University of Toledo College of Medicine and Life Sciences, Toledo, Ohio. [5]USC Norris Comprehensive Cancer Center, Los Angeles, California. [6]University of Oxford, Oxford, United Kingdom. [7]Royal Marsden NHS Foundation Trust, London, United Kingdom. [8]Virginia Commonwealth University, Richmond, Virginia. [9]Augusta University (Georgia Regents University), Augusta, Georgia. [10]University of Alabama at Birmingham, Birmingham, Alabama. [11]The University of Chicago Medicine, Chicago, Illinois. [12]University of Florida, Gainesville, Florida. [13]Juravinski Cancer Centre, Hamilton, Canada. [14]Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Canada. [15]Department of Oncology, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom. [16]Cancer Institute University College London, UCL, United Kingdom. [17]Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland. [18]Northwell Health Gynecologic Oncology, Bay Shore, New York. [19]Women's Cancer Care, Covington, Los Angeles. [20]St James University Hospital, Leeds, United Kingdom. [21]Indiana University School of Medicine, IU Simon Cancer Center, Bloomington, Indiana. [22]Astex Pharmaceuticals, Cambridge, United Kingdom. [23]Astex Pharmaceuticals Inc., Pleasanton, California. [24]Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

Clinical Trial registration ID: NCT01696032.

Corresponding Author: Daniela Matei, Northwestern University, 303 E Superior Street, Chicago, IL 60610. Phone: 312-503-4853; Fax: 312-503-4853; E-mail: Daniela.matei@northwestern.edu

Clin Cancer Res 2020;26:1009–16

doi: 10.1158/1078-0432.CCR-19-1638

Translational Relevance

Although women with ovarian cancer initially respond to platinum-based chemotherapy, platinum-resistance commonly develops, leading to fatal outcomes. We set out to determine if epigenetic priming with a hypomethylating agent (HMA) prior to carboplatin improved progression-free survival (PFS) in platinum-resistant ovarian cancer when compared with physician's choice chemotherapy in a randomized phase II trial. The median PFS and overall survival were not different, but the 6-month PFS rate was higher in the experimental group. Myelosuppression was the main toxicity observed with the experimental regimen and hypomethylating activity was measurable in PBMCs. Further development of the strategy will require identification of predictive biomarkers for patient selection.

activity in platinum-resistant HGSOC by conducting a randomized phase II trial. The objectives were to measure and compare clinical outcomes of a combination regimen of the DNA methyltransferase inhibitor (DNMTI), guadecitabine, and carboplatin, versus FDA-approved physician's choice chemotherapy (liposomal doxorubicin, weekly paclitaxel, topotecan, or gemcitabine). Guadecitabine is a dinucleotide linking decitabine to guanosine via a phosphodiester bond. Guadecitabine is resistant to degradation by cytidine deaminase and has a longer half-life compared with other DNMTIs. In a dose-finding phase I trial (17), therapeutic plasma levels of decitabine persisted beyond 8 hours. This pharmacokinetic profile provides a longer window of exposure to the hypomethylating agent (HMA), potentially exposing more cancer cells undergoing S-phase to the parent drug, decitabine, and promoting hypomethylation. Guadecitabine was shown to exert antitumor activity in ovarian cancer xenografts as a single agent and in combination with carboplatin (11, 18, 19).

A recently reported phase I trial established the tolerable and biologically active dose of guadecitabine in combination with carboplatin (17). Guadecitabine was tolerable at 30 mg/m^2 s.c. daily for 5 days prior to carboplatin on Day 8 at an AUC of 4. Each cycle was 28 days and the regimen induced ∼20% hypomethylation of long interspersed nuclear elements (LINE-1) in peripheral blood mononuclear cells (PBMC), indicating biological activity. The phase I trial reported 3 patients with partial response (PR) and 6 patients with stable disease (SD) longer than 3 months (17), providing the rationale for conducting this randomized trial in women with platinum-resistant HGSOC. Here we report clinical outcomes with G+C as compared with physician's choice FDA-approved chemotherapy for ovarian cancer in this high-need patient population.

Patients and Methods

Trial design and patient population

This was a multicenter, randomized, open-label phase II trial conducted at 20 centers in the United States, United Kingdom, and Canada. Eligible patients were ≥18 years old with platinum-resistant histologically or cytologically confirmed recurrent high-grade serous, or grade 2–3 endometrioid, mixed cell or clear cell epithelial ovarian cancer; primary peritoneal carcinoma (PPC); or fallopian tube cancer. All patients were required to have received carboplatin and taxanes. Platinum-resistance was defined as recurrence within 6 months of the last platinum-containing regimen. Patients were required to have either measurable disease according to RECIST v1.1 or detectable disease, defined as baseline values of CA-125 at least twice the upper limit of normal and one of the following: (i) ascites and/or pleural effusion attributed to tumor, or (ii) solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST definitions for target lesions. Tumor biopsies, paracentesis, or thoracentesis were performed to recover tumor cells and were required at baseline and on cycle 2 Day 8, if clinically safe and feasible. Eligible patients had acceptable organ function based on laboratory data, Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 and were ≥3 weeks from their last therapy. Exclusion criteria included carboplatin hypersensitivity, prior HMA therapy, progression on platinum treatment, left ventricular ejection fraction <50%, grade 2 or greater peripheral neuropathy, known brain metastases, other malignancies, active infections, or life-threatening illnesses. The trial was conducted in accordance with the International Council for Harmonisation Good Clinical Practice guidelines and applicable local regulatory requirements according to the Declaration of Helsinki. Local Institutional Review Boards and Independent Ethics Committees reviewed and approved the protocol and the informed consent form. Patients provided written informed consent before enrollment. The trial is registered on ClinicalTrials.gov as NCT01696032. Trial protocol and amendments are available as Supplements S1 and S2, respectively.

Randomization, trial intervention, and clinical outcomes

Eligible subjects were randomly assigned (1:1) to receive a 28-day treatment cycle of either a G+C combination treatment (guadecitabine 30 mg/m^2 s.c. once daily on days 1–5 and carboplatin intravenously AUC 4 on day 8), or treatment of choice (TC) of topotecan intravenously (3.5–4.0 mg/m^2/week administered on days 1, 8, and 15), pegylated liposomal doxorubicin intravenously (PLD; 40–50 mg/m^2 administered on day 1), paclitaxel intravenously (60–80 mg/m^2/week administered on days 1, 8, 15, and 22), or gemcitabine intravenously (800–1,000 mg/m^2 administered on days 1, 8 and 15); TC in the TC arm was at the investigator's discretion. Randomization was stratified by number of prior chemotherapies and by treatment center using an unblinded approach using a centralized web-based system. Concomitant medications and therapies were allowed, as deemed necessary for supportive care and safety of subjects; administration of other anticancer agents was not permitted. Treatment in both arms continued until disease progression or unacceptable toxicity. If the investigator decided to stop carboplatin treatment after four or more cycles, guadecitabine could be continued until progression or initiation of an alternative anticancer treatment. Crossover from the TC arm to the G+C arm was permitted after evidence of disease progression in the standard therapy arm.

The primary endpoint was PFS. Secondary efficacy endpoints included objective response rate [(ORR) defined as complete response (CR) and partial response (PR) based on both measurable and evaluable disease], PFS at 6 months, clinical benefit rate (CBR: defined as CR+ PR + SD for at least 3 months), proportion of patients with CA-125 reduction of at least 50%, duration of response (DOR), and overall survival (OS); in subjects crossing over from the TC to the G+C arm, ORR was measured. Response was assessed using RECIST v1.1 for patients with measurable disease (20), and modified Rustin criteria for patients with detectable disease according to CA-125 criteria (21, 22). Tumor measurements were obtained by CT or MRI at screening, after every two cycles for the first six cycles, and every 3 months until progression.



Figure 1.
Disposition of subjects in the trial. AUC indicates the target area under the concentration vs. time curve.

Safety was assessed by subject reported and investigator observed adverse event (AE) recording, along with physical examination, 12-lead electrocardiograms, hematology, chemistry, and urinalysis with each cycle. There was a 30-day (+5 day) safety visit after the last treatment. AEs were graded by Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Treatment-emergent AEs (TEAE) were defined as events that first occurred or worsened after the first dose of trial drug given on the first day of the first treatment cycle until 30 days after the last dose of treatment. Related serious AE (SAEs) that occurred more than 30 days after the last dose were also considered TEAEs; AEs occurring after the start of an alternative anticancer treatment were not considered TEAEs. Patients lost to follow-up were included in statistical analyses to the point of their last evaluation.

Exploratory pharmacodynamic endpoints included quantitative analysis of LINE-1 methylation in PBMCs and tumor DNA, and of selected gene promoters in tumor tissue. Blood samples for methylation assays were collected weekly during cycle 1 and on day 1 and day 8 thereafter. Global DNA methylation was evaluated by sodium bisulfite pyrosequencing for LINE-1 CpGs using PyroMark Q24 as described previously (17). Ascites, pleural fluid, or fresh tumor biopsies were obtained at screening and on day 8 of cycle 2 for assessment of methylation of selected genes listed in the Supplementary Information (Supplementary Table S1). DNA was extracted from tumor biopsies or ascites using DNeasy Blood and Tissue Kit (Qiagen) and LINE-1 and specific gene pyrosequencing was performed at EpigenDx Inc.

Statistical design and analyses

It was estimated a sample size of $\geq$96 patients randomized 1:1 into two treatment arms would provide approximately 80% power to detect a difference between the two PFS curves (median PFS of 15 vs. 28 weeks for the TC and G+C arms) at 5% significance level using a two-sided log-rank test, assuming uniform accrual of subjects over 12 months, a 24-month trial duration and an exponential distribution of the PFS endpoint. PFS, OS, and 95% confidence intervals (CI) were evaluated using the Kaplan–Meier method. PFS and OS were compared using the log-rank test, whereas ORR and CBR were compared using Fisher exact test. Subjects still alive with no progression and those who withdrew were censored on the date of the last adequate tumor, CA-125, or clinical progression assessment. Subjects initiating subsequent anticancer therapy, including those who crossed over, were censored accordingly, but prior to the initiation. Survival time was censored on the last date the subject was known to be alive or lost to follow-up before reaching the event of death. Efficacy and safety data for

Table 1. Patient characteristics.

Demographics and baseline characteristics	G+C ($n = 51$)	TC ($n = 49$)	TC crossover (TC to G+C) ($n = 27$)
Age (y)			
Mean	62.0	62.1	63.7
SD	9.2	9.6	8.8
Median	62.1	62.2	64.1
Min–max	40.6–88.4	38.9–78.5	49.6–78.5
Race			
Asian	5 (10)	6 (12)	3 (11)
Black or African American	2 (4)	2 (4)	2 (7)
Native Hawaiian or Other Pacific Islander	0	1 (2)	0
White	43 (84)	40 (82)	22 (81)
Other	1 (2)	1 (2)	1 (4)
Ethnicity			
Hispanic or Latino	2 (4)	3 (6)	3 (11)
Not Hispanic or Latino	49 (96)	46 (94)	24 (89)
Diagnosis, *n* (%)			
HGSOC	39 (76)	47 (96)	
High-grade serous PPC	10 (20)	0	
High-grade serous FT cancer	2 (4)	2 (4)	
Disease assessment, *n* (%)			
Measurable disease (RECIST)	44 (86)	46 (94)	
Detectable disease (GCIC)	7 (14)	3 (6)	
ECOG performance status, *n* (%)			
0	18 (35)	23 (47)	13 (48)
1	33 (65)	25 (51)	14 (52)
2	0	1 (2)	0
Number of prior regimens, *n* (%)			
1–2	11 (22)	14 (29)	7 (26)
3–4	21 (41)	16 (33)	8 (30)
≥5	19 (37)	19 (39)	12 (44)
Number of subjects with prior bevacizumab	17 (33)	14 (28.6)	
Time since last platinum therapy[a] (days)			
Mean	288	378	
SD	245	290	

Abbreviation: FT, fallopian tube.
[a]Includes cisplatin, carboplatin, or oxaliplatin.

subjects who crossed over were tabulated separately once guadecitabine was first administered. All analyses are descriptive and inferential statistical tests and CIs were two-sided with α equal to 0.05 unless otherwise specified. The database was locked for analysis on July 7, 2016, with mature PFS data; 97 of the 100 treated patients progressed or did not survive and all patients discontinued protocol therapy at this time (**Fig. 1**). LINE-1 and gene-specific methylation level differences before and after G+C treatment were determined using paired *t* tests. SAS version 9.3 was used for all statistical analyses.

Results

One hundred and three patients with HGSOC, fallopian tube cancer, or PPC were enrolled and randomized (52 G+C, 51 TC) and 100 received treatment (51 G+C, 49 TC; **Fig. 1**). Baseline characteristics are summarized in **Table 1** and were well balanced between the two arms in terms of age, performance status, prior therapy, and ethnicity. More patients randomized to the G+C arm had PPC compared with those randomized to TC (10 vs. 0). Most subjects were white, with a median age of 62 years, and all received prior platinum-based therapy (**Table 1**). Of the patients randomized to TC, 11 received weekly paclitaxel, 15 received liposomal doxorubicin, 20 received topotecan, and 3 received gemcitabine. Patients in the G+C arm received more treatment cycles than subjects in the TC arm (median of 4.0 vs. 2.0 cycles, respectively), with 59% of subjects in the G+C arm receiving at least three cycles of treatment and 37% receiving at least six cycles of treatment versus 47% and 31% of subjects in the TC arm, respectively. Fifty-five percent of patients from the TC arm crossed over to G+C arm following progression (**Fig. 1**). Disease progression was the most common reason for discontinuing treatment (~80% of patients in each group; **Fig. 1**). The most common TEAEs occurring in more than 5% of the trial population are reported in **Table 2**. AE frequencies between the two arms were similar, but neutropenia, diarrhea, nausea, and vomiting were more common in the G+C arm (**Tables 2** and **3**).

The median duration of PFS in the G+C arm was 16.2 weeks compared with 9.1 weeks in TC arm ($P = 0.07$; **Fig. 2A**; **Table 4**). The 6-month PFS rate was 37% in the G+C arm (95% CI, 0.24–0.50) compared with 11% in the TC arm (95% CI, 0.04–0.22; $P = 0.003$) and did not meet the prespecified criterion for superiority (HR 0.686; 95% CI, 0.456–1.030; **Fig. 2** and **Table 4**). There was no difference between

Table 2. Treatment-related AEs occurring in ≥10% of patients in either arm.

AE[a]	G+C ($n = 51$)	TC ($n = 49$)
Any related event	47 (92)	43 (88)
Neutropenia[b]	36 (71)	16 (33)
Nausea	28 (55)	21 (43)
Fatigue	24 (47)	21 (43)
Injection site reaction[b,d]	20 (39)	0
Vomiting[c]	18 (35)	8 (16)
Anemia	16 (31)	23 (47)
Leukopenia	16 (31)	10 (20)
Hypomagnesaemia	12 (24)	4 (8)
Thrombocytopenia	11 (22)	12 (24)
Constipation	10 (20)	9 (18)
Decreased appetite	10 (20)	8 (16)
Stomatitis	10 (20)	12 (24)
Drug hypersensitivity[d]	9 (18)	3 (6)
Arthralgia	7 (14)	5 (10)
Diarrhea	7 (14)	5 (10)
Headache	6 (12)	1 (2)
Alopecia	5 (10)	7 (14)

[a]$P > 0.050$ unless otherwise stated.
[b]$P < 0.001$
[c]$P = 0.040$.
[d]Because of variability in reporting terms, events of injection site reaction (typically attributed to guadecitabine SQ injection), drug hypersensitivity (typically attributed to carboplatin), anaphylactic reaction, adverse drug reaction, and infusion related reaction were analyzed as a group term and were observed in 32 subjects (33%) who received the G+C treatment.

Table 3. AEs of CTCAE grade 3 or higher occurring in >1 patient in either arm.

AE[a]	G+C ($n = 51$)	TC ($n = 49$)
Any grade ≥3 events[b]	48 (94)	31 (63)
Neutropenia[b]	34 (67)	9 (18)
Leukopenia[c]	13 (25)	4 (8)
Anaemia	9 (18)	8 (16)
Bowel obstruction	12 (24)	8 (16)
Fatigue	6 (12)	6 (12)
Diarrhea	3 (6)	0
Thrombocytopenia	3 (6)	4 (8)
Vomiting	3 (6)	4 (8)
Abdominal distension	2 (4)	1 (2)
Abdominal pain	2 (4)	2 (4)
Ascites	2 (4)	2 (4)
Hypertension	2 (4)	2 (4)
Hypokalemia	2 (4)	3 (6)
Nausea	2 (4)	4 (8)
Pyrexia	2 (4)	0
Decreased appetite	1 (2)	2 (4)
Dehydration	1 (2)	2 (4)
Pulmonary embolism	1 (2)	2 (4)
Pneumonia	0	2 (4)
Sepsis	0	2 (4)

[a]$P > 0.050$ unless otherwise stated.
[b]$P < 0.001$.
[c]$P = 0.032$.

the two arms in OS (43 and 40 weeks in the G+C and TC arms, respectively; **Fig. 2B**; **Table 4**), OS survival rate at 6 months (0.72 and 0.67 in the G+C and TC arms, respectively; **Table 4**), overall response rate (ORR; 16% and 8% in the G+C and TC arms, respectively; **Table 4**), or clinical benefit response by RECIST v1.1 or CA-125 (**Table 4**; Supplementary Table S2). Twenty-seven patients from the TC arm crossed over post-progression into the G+C arm and received a median of three cycles (14 subjects received ≥3 cycles and 5 subjects received ≥6 cycles) with a CA-125 response being confirmed in 6 of 21 evaluable subjects (29%). Patient disposition and outcomes are included in Supplementary Table S3.

To determine the biological activity of the G+C regimen, LINE-1 methylation was assessed in PBMCs from 48 patients randomized to the G+C arm. Similar to the first stage of this trial (17), LINE-1 hypomethylation approximated 20% (C1D8 vs. C1D1; range +15% to −55%; Supplementary Fig. S1A; ref. 17). In 15 patients who continued treatment beyond two cycles and for whom PBMCs were available, LINE-1 hypomethylation observed during cycle 1 was maintained or increased during subsequent cycles (Supplementary Fig. S1B), indicating that G+C maintains its biological effects throughout treatment. Correlation between clinical response and pharmacodynamic effects as measured by LINE-1 hypomethylation in PBMCs was not observed. Promoter methylation of selected genes representing TSGs (23, 24) or tumor antigens known to be methylated in ovarian cancer (25, 26) was measured in bisulfite-converted DNA obtained from paired tumor biopsies on C1D1 and C2D8 ($n = 8$ paired specimens). Treatment-induced hypomethylation of *MAGE-A2* and *MAGE-A3* promoters in tumor DNA was significant (Supplementary Fig. S1C). A nonsignificant decrease in promoter CpG methylation was also observed for LINE-1 and for the tumor antigens *NY-ESO-1* and *MAGE-A11*, but not for the TSGs *RASSF1A, MLH1*, and *BRCA1* (data not shown) or for the differentiation associated gene *HOXA11*. Taken together, these results provide evidence that G+C treatment exerts *in vivo* hypomethylating activity detectable in PBMCs and tumors.

Discussion

This is the first randomized study comparing a regimen of G+C to standard of care chemotherapy for recurrent platinum-resistant ovarian cancer. Although the 6-month PFS rate was higher in the G+C arm than the TC arm, the study did not meet its primary endpoint in this heavily pretreated population. These results are comparable with previous single-arm phase II studies using an epigenetic priming with decitabine (13, 14) or 5-azacitadine (15) prior to carboplatin. Those trials used repetitive low doses of DNMTIs, which is similar to the strategy employed with this class of HMAs in hematologic malignancies (27, 28). The repetitive administration of the HMA increases drug exposure of cells undergoing S-phase and incorporation of the nucleoside analogue into the replicating DNA, trapping DNMTs, and inhibiting *de novo* methylation.

In contrast, a previous trial conducted by the Scottish Gynecological Trials Group that used bolus administration of decitabine on day 1 prior to administration of carboplatin a week later was prematurely closed due to high hematologic toxicity and indicated lower efficacy of the combination regimen compared with carboplatin alone (29). This trial reported reduction in efficacy with the addition of decitabine to patients with partially platinum-sensitive recurrence when given in conjunction with carboplatin (29). Whether the difference in administration (bolus vs. low-dose repetitive administration) was solely responsible for the differences



Figure 2.

Survival of subjects assigned to G+C arm versus TC arm. **A,** Kaplan–Meier estimates of PFS with the G+C treatment and TC regimens. **B,** Kaplan–Meier estimates of OS with the G+C treatment and TC regimens. For subjects in the TC group who crossed over to receive G+C, OS time was censored at the crossover time point.

in levels of clinical activity remains unknown. The clinical efficacy differences with this trial may be attributable to the Scottish trial's inclusion of less heavily pretreated subjects who retained partial platinum sensitivity. Because increased DNA methylation is observed in advanced bladder cancer, colon cancer, cholangiocarcinoma, and germ cell tumors (30), DNMTI-induced sensitization to platinum or to chemotherapy is also explored in these settings with early promising results having been reported recently in colon cancer (31).

The G+C regimen had myelosuppression as the main toxicity. Prolonged neutropenia required growth factor support in >80% of the patient population to maintain the intended every 4 weeks administration of the combination. However, infections were rare and no episodes of neutropenic sepsis were recorded. Hypersensitivity and other adverse infusion reactions were observed in 9 (18%) and 8 (15%) patients in the G+C arm compared with 6% in the TC arm in this trial, which is concordant with similar observations from prior trials of DNMTIs and carboplatin (13, 29). This is most likely due to increased exposure to platinum therapy in the experimental arm, but it is also possible HMA treatment may augment type II allergic reactions.

The study has few limitations. Although all patients in this trial had platinum-resistant disease, platinum-refractory disease was excluded. Given that carboplatin was not included among the potential control regimens, and could conceivably induce clinical benefit in selected patients, this trial cannot exclude the activity of single-agent carboplatin in this population. In addition, topotecan administration in the TC arm followed a weekly administration schedule. Although this schedule was favored among treating oncologists due to its favorable toxicity profile and early reports of activity (32), the regimen was subsequently shown to induce a decreased response rate compared with the schedule using daily administration for 5 days, although OS was not affected (33). Chemotherapy with bevacizumab became FDA-approved and an accepted standard for patients with platinum-resistant ovarian cancer after results of Aurelia trial were reported (34), which occurred after the inception of this protocol. Of note is that prior therapy with bevacizumab was not excluded, and 33 patients enrolled in this trial had received bevacizumab. The shorter median PFS observed in the control group of this study (∼2 months) compared with the Aurelia trial (3.4 months; 34) reflects a more heavily pretreated group patients included here (mean of 3–4 prior regimens) for whom limited treatment options currently exist.

High-quality nucleic acids were extracted from tumor biopsies from 40 subjects at baseline and from 8 patients after two cycles of G+C. The precise mechanism by which G+C induces antitumor responses remains unknown. Our tissue- and cell-based analyses showed a number of genes and pathways involved in DNA repair and response to chemotherapy (e.g., *DOK2, miR193a, 14-3-3σ, RASSF1A*) are silenced through promoter methylation and re-expressed after guadecitabine treatment (35). Using overexpression or knockdown strategies, we have shown some of these pathways restore platinum sensitivity in ovarian cancer cell lines and xenografts (10, 35). It is likely that not one gene, but a more global

Table 4. Survival and response.

	G+C[a] (*n* = 51)	TC (*n* = 49)	*P* value
Survival			
PFS, median in weeks (95% CI)	16.3 (9–24.1)	9.1 (7.4–15)	0.0654[b]
PFS rate at 6 months, median (95% CI)	0.37 (0.24–0.50)	0.11 (0.04–0.22)	0.0027[c]
OS, (TC censored) median in weeks (95% CI)	47.3 (33–59.3)	31.5 (20.7–53.1)	0.5852[b]
OS rate at 6 months, (TC censored) median (95% CI)	0.72 (0.58–0.83)	0.67 (0.47–0.80)	0.5629[c]
Response Rate			
ORR (CR/FR+PR), *n* (%)	8 (16)	4 (8)	0.3580[d]
(95% CI)	(7.0–28.6)	(2.3–19.6)	
CBR (CR/FR+PR+SD), *n* (%)	21 (41)	14 (29)	0.2130[d]
(95% CI)	(27.6–55.8)	(16.6–43.3)	
DOR in responders			
Number of responders	21	14	
Median duration, weeks (95% CI)	26.6 (21–34.4)	24.7 (17.3–38.1)	
CA-125 response, *n*	42	41	
Number (%) of subjects with ≥50% reduction	15 (36)	13 (32)	
Median best % change from baseline (min, max)	−43 (−98–154)	−10 (−98–248)	

Note: Subjects were primarily assessed by RECIST, but in the event that an enrolled subject with measurable disease was not evaluable by RECIST (e.g., inadequate follow up scan) and had evaluable data by GCIC CA-125 criteria, the latter was used. From the G group, there were five PR by RECIST of 44 evaluable and three PR/FR by GCIC of 7 subjects with detectable disease. From the TC group, there were four PR by RECIST of 44 evaluable and zero PR/FR of three evaluable by GCIC CA-125 criteria.

Abbreviations: CRc, composite complete response; FR, full response per GCIC criteria.

[a]Guadecitabine 30 mg/m^2 on days 1 to 5 and carboplatin AUC 4 on day 8 of 28-day treatment cycles.

[b]Log-rank test for the overall PFS or OS curve.

[c]χ^2 test.

[d]Fisher exact test.

genomic program is reactivated in response to DNA hypomethylation, allowing tumor cells to undergo apoptosis in response to chemotherapy. Because preclinical models show that guadecitabine selectively eliminates chemotherapy-resistant ovarian cancer stem cells (11) by inducing a cellular differentiation program, the G+C regimen may exert antitumor activity through multiple mechanisms. The low number of posttreatment biopsies collected in the trial limits the strength of the conclusions we can draw regarding the mechanisms elicited by this HMA *in vivo*.

This randomized trial demonstrated that epigenetic priming in combination with carboplatin did not increase PFS compared with standard chemotherapy, but improved 6-month PFS in platinum-resistant ovarian cancer. Although these results do not support development of this strategy for an unselected population, they suggest a subgroup of patients might have benefitted from G+C treatment. Future studies should focus on developing predictive markers to enrich a patient population more likely to benefit from the use of HMAs.

Disclosure of Potential Conflicts of Interest

U.A. Matulonis is an advisory board member/unpaid consultant for Novartis, 2X21, and Immunogen. A.A. Secord is an employee/paid consultant for Alexion, Aravive, Astex, AstraZeneca, Clovis, Janssen/Johnson & Johnson, Merck, Mersana, Oncoquest, Roche/Genentech, Tesaro, and Eisai, and reports receiving commercial research grants from Astellas Pharma Inc., Amgen, Astex Pharmaceuticals Inc., Boehringer Ingelheim, Eisai, Endocyte, Exelixis, Merck, PharmaMar, Roche/Genentech, Tesaro, Seattle Genetics, and is an advisory board member/unpaid consultant for AstraZeneca, AbbVie, Tesaro, and Merck/Eisai. S.P. Blagden reports receiving commercial research grants from Nucana PLC, reports receiving speakers bureau honoraria from Nucana PLC and Ellipses Pharma, and holds ownership interest (including patents) in RNA Guardian Ltd. (self and immediate family members). S. Banerjee is an employee/paid consultant for AstraZeneca, Tesaro, Clovis, Merck Serono, Roche, Pharmamar, and Seattle Genetics, and reports receiving other remuneration from Nucana. S. Ghamande is an employee/paid consultant for and reports receiving speakers bureau honoraria from Tesaro. G.F. Fleming reports receiving other commercial research support from Corcept and reports receiving speakers bureau honoraria from Curio Science/Vaniam, and is an advisory board member/unpaid consultant for AbbVie and TTC Oncology. H.W. Hirte reports receiving speakers bureau honoraria from AstraZeneca and Merck, and reports receiving other remuneration from Roche. B. Basu, S. Jueliger. A. Oganesian, S. Naim, Y. Hao, H. Keer, and M. Azab, are employees/paid consultants for Astex Pharmaceuticals Inc. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: A.M. Oza, D.K. Armstrong, K.P. Nephew, A. Oganesian, S. Naim, H. Keer, M. Azab, D. Matei

Development of methodology: R. Kristeleit, G.D. Hall, A. Oganesian, S. Naim, H. Keer, M. Azab, D. Matei

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): U.A. Matulonis, A.A. Secord, J. Nemunaitis, L.D. Roman, S.P. Blagden, S. Banerjee, W.P. McGuire, S. Ghamande, M.J. Birrer, G.F. Fleming, M.J. Markham, H.W. Hirte, D.M. Provencher, B. Basu, R. Kristeleit, D.K. Armstrong, B. Schwartz, P. Braly, G.D. Hall, S. Jueliger, D. Matei

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): U.A. Matulonis, S. Banerjee, S. Ghamande, M.J. Birrer, H.W. Hirte, R. Kristeleit, D.K. Armstrong, K.P. Nephew, A. Oganesian, Y. Hao, H. Keer, M. Azab, D. Matei

Writing, review, and/or revision of the manuscript: A.M. Oza, U.A. Matulonis, A.A. Secord, J. Nemunaitis, L.D. Roman, S.P. Blagden, S. Banerjee, S. Ghamande, M.J. Birrer, G.F. Fleming, M.J. Markham, H.W. Hirte, D.M. Provencher, B. Basu, R. Kristeleit, D.K. Armstrong, P. Braly, G.D. Hall, K.P. Nephew, S. Jueliger, A. Oganesian, H. Keer, D. Matei

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A.M. Oza, W.P. McGuire, M.J. Birrer, K.P. Nephew, H. Keer, D. Matei

Study supervision: A.M. Oza, A.A. Secord, M.J. Birrer, R. Kristeleit, G.D. Hall, S. Jueliger, S. Naim, H. Keer, M. Azab, D. Matei

Other (clinical operations): S. Naim

Acknowledgments

This work was funded in part by the NCI Award CA182832-01 and the V-Foundation (to D. Matei and K.P. Nephew). Imperial, UCH, and Royal Marsden Hospitals are supported as CRUK and Experimental Cancer Medicine Centres (ECMC). This study was supported in part by Astex Pharmaceuticals Inc. Medical writing support was provided by Paul Sobol and Ryan Draker from Six Degrees Medical Consulting and funded by Astex Pharmaceuticals Inc.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 30, 2019; revised September 16, 2019; accepted December 5, 2019; published first December 12, 2019.

References

1. American Cancer Society. Cancer Facts and Figures 2018. Atlanta GA: American Cancer Society.
2. Liu CM. Cancer of the ovary. New Engl J Med 2005;352:1268–9.
3. Sandercock J, Parmar MK, Torri V, Wian W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer 2002;87:815–24.
4. Watts GS, Futscher BW, Holtan N, Degeest K, Domann FE, Rose SL. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics 2008;1:47.
5. Barton CA, Hacker NF, Clark SJ, O'Brien PM. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 2008;109:129–39.
6. Balch C, Fang F, Matei DE, Huang TH, Nephew KP. Minireview: epigenetic changes in ovarian cancer. Endocrinology 2009;150:4003–11.
7. Barton CA, Clark SJ, Hacker NF, O'Brien PM. Epigenetic markers of ovarian cancer. Adv Exp Med Biol 2008;622:35–51.
8. Plumb JA, Finn PW, Williams RJ, Bandara MJ, Watkins CJ, La Thangue NB, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003;2:721–8.
9. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000;60:6039–44.
10. Fang F, Munck J, Tang J, Taverna P, Wang Y, Miller DF, et al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin Cancer Res 2014;20:6504–16.
11. Wang Y, Cardenas H, Fang F, Condello S, Taverna P, Segar M, et al. Epigenetic targeting of ovarian cancer stem cells. Cancer Res 2014;74:4922–36.
12. Fang F, Zuo Q, Pilrose J, Wang Y, Shen C, Li M, et al. Decitabine reactivated pathways in platinum resistant ovarian cancer. Oncotarget 2014;5:3579–89.
13. Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 2012;72:2197–205.
14. Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, et al. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 2010;116:4043–53.
15. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 2011;117:1661–9.
16. Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007;25:4603–9.
17. Matei D, Ghamande S, Roman L, Alvarez Secord A, Nemunaitis J, Markham MJ, et al. A phase I clinical trial of guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer: clinical, pharmacokinetic, and pharmacodynamic analyses. Clin Cancer Res 2018;24:2285–93.
18. Wang Y, Zong X, Mitra S, Mitra AK, Matei D, Nephew KP. IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells. JCI Insight 2018;3:pii:122360.
19. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009;8:158–66.
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.
21. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003;21:187s–93s.
22. Rustin GJ, Bast RC Jr, Kelloff GJ, Barrett JC, Carter SK, Nisen PD, et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 2004;10:3919–26.
23. Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 2004;64:6476–81.
24. Imura M, Yamashita S, Cai LY, Furuta JI, Wakabayashi M, Yasugi T, et al. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 ovarian cancer cell lines. Cancer Lett 2006;241:213–20.
25. Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, et al. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res 2014;2:37–49.
26. Zhang W, Barger CJ, Link PA, Mhawech-Fauceglia P, Miller A, Akers SN, et al. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer. Epigenetics 2015;10:736–48.
27. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005;23:3948–56.
28. Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol 2015;16:1099–110.
29. Glasspool RM, Brown R, Gore ME, Rustin GJ, McNeish IA, Wilson RH, et al. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs. carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. Br J Cancer 2014;110:1923–9.
30. Albany C, Hever-Jardine MP, von Herrmann KM, Yim CY, Tam J, Warzecha JM, et al. Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine. Oncotarget 2017;8:2949–59.
31. Lee V, Wang JS, Zahurak ML, Gootjes E, Verheul HM, Parkinson R, et al. A phase I trial of a guadecitabine (SGI-110) and irinotecan in metastatic colorectal cancer patients previously exposed to irinotecan. Clin Cancer Res 2018;24:6160–7.
32. Levy T, Inbar M, Menczer J, Grisaru D, Glezerman M, Safra T. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer. Gynecol Oncol 2004;95:686–90.
33. Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2011;29:242–8.
34. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014;32:1302–8.
35. Fang F, Cardenas H, Huang H, Jiang G, Perkins SM, Zhang C, et al. Genomic and epigenomic signatures in ovarian cancer associated with re-sensitization to platinum drugs. Cancer Res 2018;78:631–644.